The emergence of mephedrone and various synthetic cathinones has introduced issues for lawmakers and regulatory companies tasked with managing the proliferation of latest psychoactive substances. The dynamic mother nature of synthetic drug generation, coupled with the power of chemists to change molecular buildings to evade authorized constraints,